ArticleClinical pharmacology and therapeutics2026
Longitudinal Analysis of Manually and Automatically Classified Circulating Tumor Biomarkers and their Prediction of Survival in Metastatic Colorectal Cancer.
Article in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Empowering Clinical Development With Disease Progression Modeling: Recommendations From the Clinical Trials Transformation Initiative.Clinical and translational science · 2026Article
- Sustainability in Pharmaceutical Research and Development: A Perspective on Opportunities for Clinical Pharmacology and Translational Sciences.Clinical pharmacology and therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating tumor cells (CTCs) and tumor-derived extracellular vesicles (tdEVs) are promising biomarkers for predicting survival and informing treatment decisions in metastatic colorectal cancer (mCRC); yet their clinical application remains limited. In this study, we analyzed CellSearch image archives from 446 patients with mCRC treated in the CAIRO2 study to evaluate the predictive value of CTCs and tdEVs and explore their utility in guiding personalized therapy. Using pharmacodynamic modeling, we examined longitudinal changes in manually and automatically classified CTC and tdEV counts, assessing their relationship with tumor size dynamics and overall survival. Automated tdEV counts demonstrated the strongest association with survival, followed by automated CTCs, which outperformed manually assessed counts. The combination of automated tdEVs and manual CTCs further improved predictive performance. Simulations predict transitioning high-risk patients (CTC/tdEV score >1.75) to second-line FOLFIRI at week 4 or 10 improves median survival from 15.1 months (12.8-18.4 CI) to 22.7 months (17.1-35.8 CI), and from 13.3 months (10.5-21.7 CI) to 23.3 months (17.8-31.2 CI), respectively. Additionally, biomarker monitoring demonstrated reduced cost (€3,913 vs. €7,802) and environmental burden (10 kg vs. 167 kg CO
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.